New therapeutic options for HCV infection in the monoclonal antibody era

New Microbiologica

Volumn 35, Issue 4, 2012, Pages 387-397

  Sautto, Giuseppe Andrea ^a   Diotti, Roberta Antonia ^a   Clementi, Massimo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Anti HCV E2 mAbs; Hcv; MAbs; Viral escape

Indexed keywords

GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; REVIEW; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 84869202423     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. AGNELLO V., ABEL G., ELFAHAL M., KNIGHT G.B., ZHANG Q.X. (1999). Hepatitis C virus and other flaviviri-dae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 96 (22), 12766-12771. (Pubitemid 29513577)
2. ALBECKA A., MONTSERRET R., KREY T., TARR A.W., DIESIS E., BALL J.K., DESCAMPS V., DUVERLIE G., REY F., PENIN F., DUBUISSON J. (2011). Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J. Virol. 85 (4), 1777-1792.
3. ALTER M.J., MARGOLIS H.S., KRAWCZYNSKI K., JUDSON F.N., MARES A., ALEXANDER W.J., HU P.Y., MILLER J.K., GERBER M.A., SAMPLINER R.E., ET AL. (1992). The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N. Engl. J. Med. 327 (27), 1899-1905. (Pubitemid 23006964)
4. ASCIONE A., TARTAGLIONE T., DI COSTANZO G.G. (2007). Natural history of chronic hepatitis C virus infection. Dig. Liver. Dis. 39 (Suppl. 1), S4-S7. (Pubitemid 47532945)
5. BARTH H., SCHAFER C., ADAH M. I., ZHANG F., LINHARDT R. J., TOYODA H., KINOSHITA-TOYODA A., TOIDA T., VAN KUPPEVELT T.H., DEPLA E., VON WEIZSACKER F., BLUM H.E., BAUMERT T.F. (2003). Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278 (42), 41003-41012. (Pubitemid 37280923)
6. BARTOSCH B., BUKH J., MEUNIER J.C., GRANIER C., ENGLE R.E., BLACKWELDER W.C., EMERSON S.U., COSSET F.L., PURCELL R.H. (2003a). In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. USA. 100 (24), 14199-14204. (Pubitemid 37499214)
7. BARTOSCH B., VERNEY G., DREUX M., DONOT P., MORICE Y., PENIN F., PAWLOTSKY J.M., LAVILLETTE D., COSSET F.L. (2005). An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79 (13), 8217-8229. (Pubitemid 40853525)
8. BARTOSCH B., VITELLI A., GRANIER C., GOUJON C., DUBUISSON J., PASCALE S., SCARSELLI E., CORTESE R., NICOSIA A., COSSET F.L. (2003b). Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278 (43), 41624-41630. (Pubitemid 37310418)
9. BENEDICTO I., MOLINA-JIMENEZ F., BARTOSCH B., COSSET F.L., LAVILLETTE D., PRIETO J., MORENO-OTERO R., VALENZUELA-FERNANDEZ A., ALDABE R., LOPEZ-CABRERA M., MAJANO P.L. (2009). The tight junction-associated protein occludin is required for a post-binding step in hepatitis C virus entry and infection. J. Virol. 83 (16), 8012-8020.
10. BJORO K., FROLAND S.S., YUN Z., SAMDAL H.H., HAALAND T. (1994). Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N. Engl. J. Med. 331 (24), 1607-1611. (Pubitemid 24372058)
11. BRIMACOMBE C.L., GROVE J., MEREDITH L.W., HU K., SYDER A.J., FLORES M.V., TIMPE J.M., KRIEGER S.E., BAUMERT T.F., TELLINGHUISEN T.L., WONG-STAAL F., BALFE P., MCKEATING J.A. (2011). Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J. Virol. 85 (1), 596-605.
12. BROERING T.J., GARRITY K.A., BOATRIGHT N.K., SLOAN S.E., SANDOR F., THOMAS W.D., JR., SZABO G., FINBERG R.W., AMBROSINO D.M., BABCOCK G.J. (2009). Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83 (23), 12473-12482.
13. BUGLI F., MANCINI N., KANG C.Y., DI CAMPLI C., GRIECO A., MANZIN A., GABRIELLI A., GASBARRINI A., FADDA G., VARALDO P.E., CLEMENTI M., BURIONI R. (2001). Mapping B-cell epitopes of hepatitis C virus E2 gly-coprotein using human monoclonal antibodies from phage display libraries. J. Virol. 75 (20), 9986-9990. (Pubitemid 32900134)
14. BURIONI R., BUGLI F., MANCINI N., ROSA D., DI CAMPLI C., MORONCINI G., MANZIN A., ABRIGNANI S., VARALDO P.E., CLEMENTI M., FADDA G. (2001). Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology. 288 (1), 29-35. (Pubitemid 32846471)
15. BURIONI R., CANDUCCI F., MANCINI N., CLEMENTI N., SASSI M., DE MARCO D., DIOTTI R.A., SAITA D., SAMPAOLO M., SAUTTO G., PIANEZZE M., CLEMENTI M. (2010). Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology. 399 (1), 144-152.
16. BURIONI R., CANDUCCI F., MANCINI N., CLEMENTI N., SASSI M., DE MARCO D., SAITA D., DIOTTI R.A., SAUTTO G., SAMPAOLO M., CLEMENTI M. (2009). Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV). New Microbiol. 32 (4), 319-324.
17. BURIONI R., MANCINI N., DE MARCO D., CLEMENTI N., PEROTTI M., NITTI G., SASSI M., CANDUCCI F., SHVELA K., BAGNARELLI P., MASCOLA J. R., CLEMENTI M. (2008a). Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One. 3 (10), e3423.
18. BURIONI R., PEROTTI M., MANCINI N., CLEMENTI M. (2008b). Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J. Hepatol. 49 (2), 299-300.
19. BURIONI R., PLAISANT P., MANZIN A., ROSA D., DELLI CARRI V., BUGLI F., SOLFOROSI L., ABRIGNANI S., VARALDO P.E., FADDA G., CLEMENTI M. (1998). Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology. 28 (3), 810-814. (Pubitemid 28405434)
20. BURIONI R., WILLIAMSON R. A., SANNA P. P., BLOOM F.E., BURTON D.R. (1994). Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro. Proc. Natl. Acad. Sci. USA. 91 (1), 355-359. (Pubitemid 24018703)
21. CATANESE M.T., ANSUINI H., GRAZIANI R., HUBY T., MOREAU M., BALL J.K., PAONESSA G., RICE C.M., CORTESE R., VITELLI A., NICOSIA A. (2010). Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J. Virol. 84 (1), 34-43.
22. CHANDRA P.K., HAZARI S., POAT B., GUNDUZ F., PRABHU R., LIU G., BURIONI R., CLEMENTI M., GARRY R. F., DASH S. (2010). Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol. J. 7, 118.
23. CLAYTON R.F., OWSIANKA A., AITKEN J., GRAHAM S., BHELLA D., PATEL A.H. (2002). Analysis of anti-genicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J. Virol. 76 (15), 7672-7682. (Pubitemid 34760991)
24. CLEMENTI N., DE MARCO D., MANCINI N., SOLFOROSI L., MORENO G.J., GUBAREVA L.V., MISHIN V., DI PIETRO A., VICENZI E., SICCARDI A.G., CLEMENTI M., BURIONI R. (2011). A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 6 (12), e28001.
25. CLEMENTI N., MANCINI N., SOLFOROSI L., CASTELLI M., CLEMENTI M., BURIONI R. (2012). Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int. J. Mol. Sci. 13 (7), 8273-8292.
26. DE MARCO D., CLEMENTI N., MANCINI N., SOLFOROSI L., MORENO G.J., SUN X., TUMPEY T.M., GUBAREVA L.V., MISHIN V., CLEMENTI M., BURIONI R. (2012). A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One. 7 (4), e34415.
27. DI LORENZO C., ANGUS A.G., PATEL A.H. (2011). Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses. 3 (11), 2280-2300.
28. DOWD K.A., NETSKI D.M., WANG X.H., COX A.L., RAY S.C. (2009). Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology. 136 (7), 2377-2386.
29. DREUX M., PIETSCHMANN T., GRANIER C., VOISSET C., RICARD-BLUM S., MANGEOT P.E., KECK Z., FOUNG S., VU-DAC N., DUBUISSON J., BARTENSCHLAGER R., LAVILLETTE D., COSSET F.L. (2006). High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281 (27), 18285-18295. (Pubitemid 44035485)
30. DRUMMER H.E., BOO I., MAERZ A.L., POUMBOURIOS P. (2006). A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J. Virol. 80 (16), 7844-7853. (Pubitemid 44182285)
31. DUBUISSON J., HSU H.H., CHEUNG R.C., GREENBERG H.B., RUSSELL D.G., RICE C.M. (1994). Formation and in-tracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68 (10), 6147-6160. (Pubitemid 24294864)
32. EL ABD Y.S., TABLL A.A., EL DIN N.G., HOSNY AEL D., MOUSTAFA R.I., EL-SHENAWY R., ATEF K., EL-AWADY M.K. (2011). Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virol. J. 8, 391.
33. EREN R., LANDSTEIN D., TERKIELTAUB D., NUSSBAUM O., ZAUBERMAN A., BEN-PORATH J., GOPHER J., BUCHNICK R., KOVJAZIN R., ROSENTHAL-GALILI Z., AVIEL S., ILAN E., SHOSHANY Y., NEVILLE L., WAISMAN T., BENMOSHE O., KISCHITSKY A., FOUNG S. K., KECK Z. Y., PAPPO O., EID A., JURIM O., ZAMIR G., GALUN E., DAGAN S. (2006). Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 80 (6), 2654-2664. (Pubitemid 43346361)
34. EVANS M. J., VON HAHN T., TSCHERNE D. M., SYDER A.J., PANIS M., WOLK B., HATZIIOANNOU T., MCKEATING J.A., BIENIASZ P.D., RICE C.M. (2007). Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 446 (7137), 801-805. (Pubitemid 46582027)
35. FERAY C., GIGOU M., SAMUEL D., DUCOT B., MAISONNEUVE P., REYNES M., BISMUTH A., BISMUTH H. (1998). Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobu-lins after liver transplantation. Ann. Intern. Med. 128 (10), 810-816. (Pubitemid 28267713)
36. FLINT M., THOMAS J.M., MAIDENS C.M., SHOTTON C., LEVY S., BARCLAY W.S., MCKEATING J.A. (1999). Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J. Virol. 73 (8), 6782-6790. (Pubitemid 29327861)
37. GALUN E., TERRAULT N.A., EREN R., ZAUBERMAN A., NUSSBAUM O., TERKIELTAUB D., ZOHAR M., BUCHNIK R., ACKERMAN Z., SAFADI R., ASHUR Y., MISRACHI S., LIBERMAN Y., RIVKIN L., DAGAN S. (2007). Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity. J. Hepatol. 46 (1), 37-44. (Pubitemid 44827422)
38. GIANG E., DORNER M., PRENTOE J.C., DREUX M., EVANS M.J., BUKH J., RICE C.M., PLOSS A., BURTON D.R., LAW M. (2012). Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. USA. 109 (16), 6205-6210.
39. HABERSTROH A., SCHNOBER E.K., ZEISEL M.B., CAROLLA P., BARTH H., BLUM H. E., COSSET F.L., KOUTSOUDAKIS G., BARTENSCHLAGER R., UNION A., DEPLA E., OWSIANKA A., PATEL A.H., SCHUSTER C., STOLLKELLER F., DOFFOEL M., DREUX M., BAUMERT T.F. (2008). Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 135 (5), 1719-1728 e1.
40. HSU M., ZHANG J., FLINT M., LOGVINOFF C., CHENG-MAYER C., RICE C. M., MCKEATING J.A. (2003). Hepatitis C virus glycoproteins mediate pH-de-pendent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. USA. 100 (12), 7271-7276. (Pubitemid 36706428)
41. IACOB R.E., KECK Z., OLSON O., FOUNG S.K., TOMER K.B. (2008). Structural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycopro-tein. Biochim. Biophys. Acta. 1784 (3), 530-542.
42. JOHANSSON D.X., VOISSET C., TARR A.W., AUNG M., BALL J.K., DUBUISSON J., PERSSON M.A. (2007). Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. USA. 104 (41), 16269-16274. (Pubitemid 350099395)
43. KATO N., SEKIYA H., OOTSUYAMA Y., NAKAZAWA T., HIJIKATA M., OHKOSHI S., SHIMOTOHNO K. (1993). Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67 (7), 3923-3930. (Pubitemid 23180716)
44. KECK Z.Y., LI T.K., XIA J., GAL-TANAMY M., OLSON O., LI S.H., PATEL A.H., BALL J. K., LEMON S.M., FOUNG S.K. (2008). Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82 (12), 6061-6066. (Pubitemid 351822282)
45. KECK Z.Y., OP DE BEECK A., HADLOCK K.G., XIA J., LI T.K., DUBUISSON J., FOUNG S.K. (2004a). Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78 (17), 9224-9232. (Pubitemid 39096532)
46. KECK Z.Y., SAHA A., XIA J., WANG Y., LAU P., KREY T., REY F.A., FOUNG S.K. (2011). Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J. Virol. 85 (20), 10451-10463.
47. KECK Z.Y., SUNG V.M., PERKINS S., ROWE J., PAUL S., LIANG T.J., LAI M.M., FOUNG S.K. (2004b). Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 78 (13), 7257-7263. (Pubitemid 38781563)
48. KECK Z.Y., XIA J., CAI Z., LI T.K., OWSIANKA A.M., PATEL A.H., LUO G., FOUNG S.K. (2007). Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J. Virol. 81 (2), 1043-1047. (Pubitemid 46067930)
49. KECK Z.Y., XIA J., WANG Y., WANG W., KREY T., PRENTOE J., CARLSEN T., LI A.Y., PATEL A.H., LEMON S.M., BUKH J., REY F.A., FOUNG S.K. (2012). Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS. Pathog. 8 (4), e1002653.
50. KONG L., GIANG E., ROBBINS J.B., STANFIELD R.L., BURTON D.R., WILSONI.A., LAW M. (2012). Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. USA. 109 (24), 9499-9504.
51. KREY T., D'ALAYER J., KIKUTI C.M., SAULNIER A., DAMIER-PIOLLE L., PETITPAS I., JOHANSSON D.X., TAWAR R.G., BARON B., ROBERT B., ENGLAND P., PERSSON M.A., MARTIN A., REY F.A. (2010). The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of themolecule. PLoS Pathog. 6 (2), e1000762.
52. KWO P.Y., LAWITZ E.J., MCCONE J., SCHIFF E.R., VIERLING J.M., POUND D., DAVIS M.N., GALATI J.S., GORDON S.C., RAVENDHRAN N., ROSSARO L., ANDERSON F.H., JACOBSON I.M., RUBIN R., KOURY K., PEDICONE L.D., BRASS C.A., CHAUDHRI E., ALBRECHT J.K. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and rib-avirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 376 (9742), 705-716.
53. LAW M., MARUYAMA T., LEWIS J., GIANG E., TARR A.W., STAMATAKI Z., GASTAMINZA P., CHISARI F.V., JONES I.M., FOX R.I., BALL J.K., MCKEATING J.A., KNETEMAN N.M., BURTON D.R. (2008). Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14 (1), 25-27.
54. LIU S., YANG W., SHEN L., TURNER J.R., COYNE C.B., WANG T. (2009). Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 83 (4), 2011-2014.
55. MAKRIS M., PRESTON F.E., ROSENDAAL F.R., UNDERWOOD J.C., RICE K.M., TRIGER D.R. (1996). The natural history of chronic hepatitis C in haemophiliacs. Br. J. Haematol. 94 (4), 746-752. (Pubitemid 26308913)
56. MANCINI N., CLEMENTI M., BURIONI R. (2012). Natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 367 (9), 871-872.
57. MANCINI N., DIOTTI R.A., PEROTTI M., SAUTTO G., CLEMENTI N., NITTI G., PATEL A.H., BALL J.K., CLEMENTI M., BURIONI R. (2009). Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One. 4 (12), e8254.
58. MANCINI N., SOLFOROSI L., CLEMENTI N., DE MARCO D., CLEMENTI M., BURIONI R. (2011). A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral. Res. 92 (1), 15-26.
59. MCHUTCHISON J.G., MANNS M.P., MUIR A.J., TERRAULT N.A., JACOBSON I.M., AFDHAL N.H., HEATHCOTE E.J., ZEUZEM S., REESINK H.W., GARG J., BSHARAT M., GEORGE S., KAUFFMAN R.S., ADDA N., DI BISCEGLIE A.M. (2010). Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362 (14), 1292-1303.
60. MEULEMAN P., HESSELGESSER J., PAULSON M., VANWOLLEGHEM T., DESOMBERE I., REISER H., LEROUX-ROELS G. (2008). Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology. 48 (6), 1761-1768.
61. MEUNIER J.C., RUSSELL R.S., GOOSSENS V., PRIEM S., WALTER H., DEPLA E., UNION A., FAULK K.N., BUKH J., EMERSON S.U., PURCELL R.H. (2008). Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82 (2), 966-973.
62. MOLINA S., CASTET V., FOURNIER-WIRTH C., PICHARDGARCIA L., AVNER R., HARATS D., ROITELMAN J., BARBARAS R., GRABER P., GHERSA P., SMOLARSKY M., FUNARO A., MALAVASI F., LARREY D., COSTE J., FABRE J.M., SA-CUNHA A., MAUREL P. (2007). The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J. Hepatol. 46 (3), 411-419. (Pubitemid 46201721)
63. MOLINA S., CASTET V., PICHARD-GARCIA L., WYCHOWSKI C., MEURS E., PASCUSSI J.M., SUREAU C., FABRE J.M., SACUNHA A., LARREY D., DUBUISSON J., COSTE J., MCKEATING J., MAUREL P., FOURNIER-WIRTH C. (2008). Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J. Virol. 82 (1), 569-574. (Pubitemid 350309172)
64. MORIN T.J., BROERING T.J., LEAV B.A., BLAIR B.M., ROWLEY K.J., BOUCHER E.N., WANG Y., CHESLOCK P.S., KNAUBER M., OLSEN D.B., LUDMERER S.W., SZABO G., FINBERG R.W., PURCELL R.H., LANFORD R.E., AMBROSINO D.M., MOLRINE D.C., BABCOCK G.J. (2012). Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathog. 8 (8), e1002895.
65. NEUMANN-HAEFELIN C., BLUM H.E., CHISARI F.V., THIMME R. (2005). T cell response in hepatitis C virus infection. J. Clin. Virol. 32 (2), 75-85. (Pubitemid 40093957)
66. OWSIANKA A., CLAYTON R.F., LOOMIS-PRICE L.D., MCKEATING J.A., PATEL A.H. (2001). Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82 (Pt 8), 1877-1883. (Pubitemid 32707551)
67. OWSIANKA A.M., TARR A.W., KECK Z.Y., LI T.K., WITTEVELDT J., ADAIR R., FOUNG S.K., BALL J.K., PATEL A.H. (2008). Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89 (Pt 3), 653-659.
68. OWSIANKA A.M., TIMMS J.M., TARR A.W., BROWN R.J., HICKLING T.P., SZWEJK A., BIENKOWSKA-SZEWCZYK K., THOMSON B.J., PATEL A.H., BALL J.K. (2006). Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80 (17), 8695-8704. (Pubitemid 44384879)
69. OWSIANKA A., TARR A.W., JUTTLA V.S., LAVILLETTE D., BARTOSCH B., COSSET F.L., BALL J.K., PATEL A.H. (2005). Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol.79 (17), 11095-11104. (Pubitemid 41170650)
70. PEROTTI M., GHIDOLI N., ALTARA R., DIOTTI R.A., CLEMENTI N., DE MARCO D., SASSI M., CLEMENTI M., BURIONI R., MANCINI N. (2008a). Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun. Rev. 7 (6), 468-472.
71. PEROTTI M., MANCINI N., DIOTTI R. A., TARR A. W., BALL J.K., OWSIANKA A., ADAIR R., PATEL A.H., CLEMENTI M., BURIONI R. (2008b). Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82 (2), 1047-1052.
72. PESTKA J.M., ZEISEL M.B., BLASER E., SCHURMANN P., BARTOSCH B., COSSET F.L., PATEL A.H., MEISEL H., BAUMERT J., VIAZOV S., RISPETER K., BLUM H.E., ROGGENDORF M., BAUMERT T.F. (2007). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA. 104 (14), 6025-6030. (Pubitemid 47175652)
73. PIAZZA M., SAGLIOCCA L., TOSONE G., GUADAGNINO V., STAZI M.A., ORLANDO R., BORGIA G., ROSA D., ABRIGNANI S., PALUMBO F., MANZIN A., CLEMENTI M. (1997). Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch. Intern. Med. 157 (14), 1537-1544. (Pubitemid 27305198)
74. PILERI P., UEMATSU Y., CAMPAGNOLI S., GALLI G., FALUGI F., PETRACCA R., WEINER A.J., HOUGHTON M., ROSA D., GRANDI G., ABRIGNANI S. (1998). Binding of hepatitis C virus to CD81. Science. 282 (5390), 938-941. (Pubitemid 28507525)
75. PLOSS A., EVANS M.J., GAYSINSKAYA V.A., PANIS M., YOU H., DE JONG Y.P., RICE C.M. (2009). Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature. 457 (7231), 882-886.
76. SAINZ B., JR., BARRETTO N., MARTIN D.N., HIRAGA N., IMAMURA M., HUSSAIN S., MARSH K.A., YU X., CHAYAMA K., ALREFAI W.A., UPRICHARD S.L. (2012). Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 18 (2), 281-285.
77. SAUTTO G., MANCINI N., DIOTTI R.A., SOLFOROSI L., CLEMENTI M., BURIONI R. (2012a). Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral. Res. 96 (1), 82-89.
78. SAUTTO G., MANCINI N., SOLFOROSI L., DIOTTI R.A., CLEMENTI M., BURIONI R. (2012b). HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role. Clin. Dev. Immunol. 2012, 705013.
79. SCARSELLI E., ANSUINI H., CERINO R., ROCCASECCA R.M., ACALI S., FILOCAMO G., TRABONI C., NICOSIA A., CORTESE R., VITELLI A. (2002). The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21 (19), 5017-5025.
80. SCHIANO T.D., CHARLTON M., YOUNOSSI Z., GALUN E., PRUETT T., TUR-KASPA R., EREN R., DAGAN S., GRAHAM N., WILLIAMS P.V., ANDREWS J. (2006). Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver. Transpl. 12 (9), 1381-1389. (Pubitemid 44405128)
81. SHIMIZU Y.K., IGARASHI H., KIYOHARA T., CABEZON T., FARCI P., PURCELL R.H., YOSHIKURA H. (1996). A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology. 223 (2), 409-412. (Pubitemid 26319606)
82. SOLFOROSI L., MANCINI N., CANDUCCI F., CLEMENTI N., SAUTTO G.A., DIOTTI R.A., CLEMENTI M., BURIONI R. (2012). A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiol. 35 (3), 289-294.
83. SONG L., SUN Z.Y., COLEMAN K.E., ZWICK M.B., GACH J.S., WANG J.H., REINHERZ E.L., WAGNER G., KIM M. (2009). Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. USA. 106 (22), 9057-9062.
84. TARR A.W., OWSIANKA A.M., TIMMS J.M., MCCLURE C.P., BROWN R.J., HICKLING T.P., PIETSCHMANN T., BARTENSCHLAGER R., PATEL A.H., BALL J.K. (2006). Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. 43 (3), 592-601.
85. TROESCH M., MEUNIER I., LAPIERRE P., LAPOINTE N., ALVAREZ F., BOUCHER M., SOUDEYNS H. (2006). Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology. 352 (2), 357-367. (Pubitemid 44216011)
86. VIEYRES G., DUBUISSON J., PATEL A.H. (2011). Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J. Gen. Virol. 92 (Pt 3), 494-506.
87. VOISSET C., CALLENS N., BLANCHARD E., OP DE BEECK A., DUBUISSON J., VU-DAC N. (2005). High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280 (9), 7793-7799. (Pubitemid 40349673)
88. WEINER A.J., GEYSEN H.M., CHRISTOPHERSON C., HALL J.E., MASON T.J., SARACCO G., BONINO F., CRAWFORD K., MARION C.D., CRAWFORD K.A., ET AL. (1992). Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA. 89 (8), 3468-3472.
89. ZHANG P., ZHONG L., STRUBLE E.B., WATANABE H., KACHKO A., MIHALIK K., VIRATA-THEIMER M.L., ALTER H.J., FEINSTONE S., MAJOR M. (2009). Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA. 106 (18), 7537-7541.